Advanced solid tumours, Phase 1/2
Alomfilimab SAR445256 (formerly KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Alomfilimab is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ICOS-positive effector T cells.
Alomfilimab can also improve the ratio of intra-tumoral effector T cells to regulatory T cells which promotes an anti-tumour immune response. In preclinical studies, we have demonstrated that Alomfilimab can promote a significant and long-lasting anti-tumour effect as monotherapy or as a synergistic combination with anti-PD-L1. We are currently conducting a Phase 1/2 clinical trial of Alomfilimab in patients with advanced solid tumours as a monotherapy and in combination with atezolizumab.
If you would like information on Sanofi’s managed access programs please see Managed Access Programs (MAPs) - Sanofi